Travere Therapeutics, Inc. (TVTX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
TVTX Q1 2026: Filspari Revenue Jumps 88% as FSGS Approval Unlocks $3B Peak Sales Path
May 05, 2026
-
Travere Therapeutics (TVTX) Q4 2025: Filspari Sales Surge 144% as IGAN Adoption Broadens, FSGS Approval Path Remains in Focus
February 23, 2026
-
Travere Therapeutics (TVTX) Q3 2025: Filspari US Sales Surge 155% as FSGS Launch Readiness Accelerates
October 30, 2025
-
Verica Pharmaceuticals (TVTX) Q1 2025: WICAN Applicator Units Jump 16.7% as Leaner Model Drives Commercial Traction
July 07, 2025
-
Travere Therapeutics (TVTX) Q1 2025: Filspari Sales Surge 182% YoY, Setting Up FSGS Launch
July 04, 2025